Upstream Bio, Inc. (UPB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Upstream Bio, Inc. stock (UPB) is currently trading at $8.45. Upstream Bio, Inc. PS ratio (Price-to-Sales) is 167.39. Analyst consensus price target for UPB is $49.75. WallStSmart rates UPB as Sell.
- UPB PE ratio analysis and historical PE chart
- UPB PS ratio (Price-to-Sales) history and trend
- UPB intrinsic value — DCF, Graham Number, EPV models
- UPB stock price prediction 2025 2026 2027 2028 2029 2030
- UPB fair value vs current price
- UPB insider transactions and insider buying
- Is UPB undervalued or overvalued?
- Upstream Bio, Inc. financial analysis — revenue, earnings, cash flow
- UPB Piotroski F-Score and Altman Z-Score
- UPB analyst price target and Smart Rating
Upstream Bio, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Upstream Bio, Inc. (UPB) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Upstream Bio, Inc. (UPB) Key Strengths (2)
93.30% of shares held by major funds and institutions
Trading at 1.24x book value, attractively priced
Supporting Valuation Data
Upstream Bio, Inc. (UPB) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 167.4x annual revenue
Small-cap company with higher risk but more growth potential
Solid revenue growth at 12.50% per year
Supporting Valuation Data
Upstream Bio, Inc. (UPB) Detailed Analysis Report
Overall Assessment
This company scores 30/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 2.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Book. Valuation metrics including Price/Book (1.24) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (167.39) suggest expensive pricing. Growth concerns include Revenue Growth at 12.50%, which may limit upside. Profitability pressure is visible in Return on Equity at -40.80%, Operating Margin at -5539.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -40.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 12.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
UPB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
UPB's Price-to-Sales ratio of 167.39x trades 49% below its historical average of 328.68x (17th percentile). The current valuation is 76% below its historical high of 708.66x set in Jan 2026, and 13% above its historical low of 148.08x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Upstream Bio, Inc. (UPB) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Upstream Bio, Inc. operates as a stable business with moderate growth and solid fundamentals. Revenue reached 3M with 13% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 1178% of revenue (33M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -22M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Upstream Bio, Inc..
Bottom Line
Upstream Bio, Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Upstream Bio, Inc.(UPB)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. The company is headquartered in Waltham, Massachusetts.